NM26-2198
Numab Therapeutics
['derm']
our team will present a poster at the 31st #eadvcongress in milan sharing preclinical data on nm26-2198, our novel bispecific antibody simultaneously blocking il-4, il-13 &amp; il-31. view our poster to learn about its potential to treat #atopicdermatitis: 
At Numab, we are writing the next chapter in #CancerImmunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies.